VolitionRx
Henderson, Nevada, United States · Biotechnology, Genetics, Health Care
VolitionRx Limited is a multi-national epigenetics company dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. The company is focused on advancing the science of epigenetics and developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of dis
Key facts
- Headquarters
- Henderson, Nevada, United States
- Employees
- 86
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (VNRX)
- Website
- volition.com
- Company page
Recent activity at VolitionRx
- : VolitionRx Secures $2.4 Million Through Convertible Note Issuance
- : VOLITIONRX LTD
- : VolitionRx and Hologic Enter Co-Marketing Agreement for Nu.Q® Discover Services.
- : VOLITIONRX LTD
- : Volition Signs Automated Cancer Test Agreement with Fujifilm Vet Systems
- : VolitionRx Limited Launches High Throughput Synthetic Sepsis Method to Aid Therapeutic Development for NETs-Related Diseases.
- : VOLITIONRX LTD
- : VolitionRx Limited Appoints Dr Andrew Retter as Chief Medical Officer
- : Volitionrx Secures Approximately $5.5 Million In Belgium Regional Government Financing From Wallonie Entreprendre
- : VOLITIONRX LTD
VolitionRx funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Convertible Note | $2.4M |
| Jan 2026 | Venture | $22.7M |
| May 2025 | Venture | $16.3M |
| Mar 2024 | Pre-Seed | $100K |
| Dec 2023 | Funding Round | $5.5M |
Leadership
- Edward Futcher, Director
- Habib Skaff, Director
- Alan Colman, Director
- Guy Innes, Director
- Martin Faulkes, Director
- Cameron Reynolds, Executive Officer, Director
- MARTIN FAULKES, Executive Officer
- ALAN COLMAN, Director
- PHILLIP BARNES, Director
- RODNEY ROOTSAERT, Executive Officer
- CAMERON REYNOLDS, Executive Officer
- MARTIN FAULKES, Executive Officer
Verified email and direct lines for VolitionRx’s decision-makers are on Fundz. See plans
VolitionRx in the news
- VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France - PR Newswire (Sep 17, 2026)
- MissionIRNewsBreaks – VolitionRx (NYSE American: VNRX) Joins €6.3 Million French Government-Funded DETECSEPS Sepsis Project - FinancialContent (Sep 17, 2026)
- Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA - PR Newswire (Mar 18, 2026)
- VolitionRx call will cover Q2 results and upcoming milestones - Stock Titan (Aug 11, 2026)
- VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets - PR Newswire (May 27, 2026)
- Volition Announces Detection of Over 95% of Early-Stage Cancers - PR Newswire (Mar 25, 2026)
- VolitionRX (VNRX) Stock Price, News & Analysis - MarketBeat (Nov 17, 2017)
- VolitionRx Participates in Launch of DETECSEPS Program in France - PR Newswire (Sep 17, 2026)
Companies similar to VolitionRx
- Passage Bio · Biotechnology, Genetics, Health Care, Therapeutics
- uniQure · Biotechnology, Genetics, Health Care, Therapeutics
- Precision BioSciences · Biotechnology, Genetics, Health Care, Therapeutics
- Franklin Biolabs · Biotechnology, Genetics, Health Care, Therapeutics
- Applied StemCell · Biotechnology, Genetics, Health Care, Therapeutics
About VolitionRx: questions and answers
What does VolitionRx do?
VolitionRx Limited is a multi-national epigenetics company dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. The company is focused on advancing the science of epigenetics and developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of dis
Where is VolitionRx headquartered?
VolitionRx is headquartered in Henderson, Nevada, United States.
How many employees does VolitionRx have?
VolitionRx has about 86 employees.
Has VolitionRx raised funding?
Yes. Fundz has recorded 5 funding events for VolitionRx. The most recent, Convertible Note of $2.4M, was in Sep 2026.
What is the latest news on VolitionRx?
On Sep 22, 2026, VolitionRx Secures $2.4 Million Through Convertible Note Issuance
Is VolitionRx a public company?
Yes. VolitionRx is publicly traded under the ticker VNRX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy